GlassScriptPhysician profile
Mohammad S Yazdanie
NPI 1467949933
$2,688.29
in general payments reported to CMS, 2019-2025
16 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $327 · 2023: $1,119 · 2024: $803 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,343.10 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $809.91 | 2023-2025 | Durysta, Lumigan, Alphagan P |
| Glaukos Corporation | $524.86 | 2022-2024 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Idose |
| Mallinckrodt Hospital Products INC. | $313.13 | 2022-2024 | Acthar |
| Bausch & Lomb Americas INC. | $274.37 | 2022-2025 | Vyzulta, Miebo, Envista Envy Iol |
| Alcon Vision LLC | $201.83 | 2022-2025 | Clareon, Rocklatan |
| Amgen INC. | $142.96 | 2024-2025 | Tepezza |
| Dompe US, INC. | $88.80 | 2022-2025 | Oxervate |
| Oyster Point Pharma, INC. | $55.35 | 2023-2024 | Tyrvaya, Ryzumvi |
| Horizon Therapeutics Plc | $52.72 | 2022-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $52.23 | 2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $39.04 | 2023 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $38.55 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $36.06 | 2022 | |
| Biotissue Holdings INC. | $25.00 | 2025 | |
| Sight Sciences, INC. | $18.66 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $14.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Yazdanie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.